• (PLX AI) – AstraZeneca announces settlement of patent litigation for Ultomiris.
  • • AstraZeneca says agreement with Chugai Pharmaceutical resolving all patent disputes
  • • Under the terms of the agreement, Alexion, AstraZeneca's Rare Disease group, will make a single payment of $775 million in the second quarter of 2022
  • • No further amounts are payable by either party
  • • The settlement does not impact AstraZeneca's financial guidance for 2022

Quelle: PLX AI